Characterization of the Response to Secukinumab in Plaque Psoriasis Using Novel Immunologic and Genetic Profiling
Phase of Trial: Phase IV
Latest Information Update: 05 May 2017
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriasis
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 02 May 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.
- 29 Jul 2016 Status changed from not yet recruiting to recruiting.